Robbie Marcus
Stock Analyst at JP Morgan
(3.88)
# 560
Out of 5,182 analysts
181
Total ratings
53.78%
Success rate
7.88%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HTFL HeartFlow | Maintains: Overweight | $40 → $35 | $26.87 | +30.26% | 3 | Mar 19, 2026 | |
| PODD Insulet | Maintains: Overweight | $415 → $340 | $202.46 | +67.93% | 5 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Neutral | $105 → $100 | $86.42 | +15.71% | 13 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $135 → $100 | $61.86 | +61.66% | 14 | Feb 5, 2026 | |
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $80.84 | +23.70% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $54.42 | +116.83% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $69.66 | +11.97% | 7 | Dec 5, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $34.54 | +50.55% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $6.76 | +33.14% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $91.40 | +9.41% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $17 | $17.88 | -4.92% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $63.11 | +18.84% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $9.33 | +39.34% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $15.92 | +0.50% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $14.47 | +10.57% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $8.37 | -16.37% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $67.40 | +78.04% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $16.62 | +116.61% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $332.07 | +34.01% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $452.95 | +49.02% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $8.84 | +47.06% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $28.89 | +38.46% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $69.73 | +29.07% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $22.52 | +122.02% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $1.35 | +494.80% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $329.96 | -24.23% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.80 | +2.94% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $101.83 | +15.88% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $118.63 | +31.50% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $115.06 | -65.24% | 2 | May 5, 2020 |
HeartFlow
Mar 19, 2026
Maintains: Overweight
Price Target: $40 → $35
Current: $26.87
Upside: +30.26%
Insulet
Feb 19, 2026
Maintains: Overweight
Price Target: $415 → $340
Current: $202.46
Upside: +67.93%
Medtronic
Feb 18, 2026
Maintains: Neutral
Price Target: $105 → $100
Current: $86.42
Upside: +15.71%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $135 → $100
Current: $61.86
Upside: +61.66%
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $80.84
Upside: +23.70%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $54.42
Upside: +116.83%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $69.66
Upside: +11.97%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $34.54
Upside: +50.55%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $6.76
Upside: +33.14%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $91.40
Upside: +9.41%
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $17.88
Upside: -4.92%
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $63.11
Upside: +18.84%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $9.33
Upside: +39.34%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $15.92
Upside: +0.50%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $14.47
Upside: +10.57%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $8.37
Upside: -16.37%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $67.40
Upside: +78.04%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $16.62
Upside: +116.61%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $332.07
Upside: +34.01%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $452.95
Upside: +49.02%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $8.84
Upside: +47.06%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $28.89
Upside: +38.46%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $69.73
Upside: +29.07%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $22.52
Upside: +122.02%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $1.35
Upside: +494.80%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $329.96
Upside: -24.23%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.80
Upside: +2.94%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $101.83
Upside: +15.88%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $118.63
Upside: +31.50%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $115.06
Upside: -65.24%